ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "morbidity and mortality"

  • Abstract Number: 557 • 2016 ACR/ARHP Annual Meeting

    Differences in Clinical Outcomes in Different Socio-Economic and Racial Groups with Rheumatoid Arthritis: Data from National Inpatient Sample

    Dilli Poudel1, Rashmi Dhital2, Abdullateef Abdulkareem3, Pragya Shrestha4 and Paras Karmacharya1, 1Internal Medicine, Reading Health System, WEST READING, PA, 2Universal College of Medical Sciences, MBBS, Kathmandu, Nepal, 3Inernal Medicine, Reading Health System, West Reading, PA, 4Internal medicine, Reading Health System, West Reading, PA

    Background/Purpose: Studies have reported differences in healthcare utilization and outcome among different socioeconomic and ethnic groups. Complications like atherosclerotic cardiovascular diseases (ASCVD) have been documented…
  • Abstract Number: 847 • 2016 ACR/ARHP Annual Meeting

    Forced Vital Capacity Predicts Lung Fibrosis Progression and Mortality in Systemic Sclerosis

    Anna Hoffmann-Vold1, Elizabeth R. Volkmann2, Oyvind Midtvedt3, Torhild Garen3, Anders Heiervang Tennøe3, Trond Mogens Aalokken4, May Brit Lund5 and Øyvind Molberg3, 1Division of Rheumatology, Oslo University Hospital, Oslo, Norway, 2University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3Rheumatology, Oslo University Hospital, Oslo, Norway, 4Radiology, Oslo University Hospital, Oslo, Norway, 5Respiratory Medicine, Oslo University Hospital, Oslo, Norway

    Background/Purpose:  Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but there are no valid methods for early detection of SSc-ILD or…
  • Abstract Number: 910 • 2016 ACR/ARHP Annual Meeting

    Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study

    Amar Oza1, Na Lu2 and Hyon K. Choi3, 1Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Boston, MA, 2Clinical Epidemiology, Boston University School of Medicine, Boston, MA, 3Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Recent studies have shown an increase in cardiovascular and all-cause mortality in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).1 The hypothesized dual role of…
  • Abstract Number: 1189 • 2016 ACR/ARHP Annual Meeting

    Inpatient Trends for Adults with Scleroderma in the United States: A 20 Year Analysis

    Noopur Goel1, Ishan Lalani2 and Iram Moledina3, 1Internal Medicine, Monmouth Medical Center, monmouth beach, NJ, 2Internal Medicine, Monmouth Medical Center, Ocean, NJ, 3Gujarat Adani Institute of Medical Sciences, New Haven, CT

  • Abstract Number: 1894 • 2016 ACR/ARHP Annual Meeting

    Increased Mortality in Systemic Sclerosis Patients with Fibrosing Myopathy

    Julie J. Paik1, Fredrick M. Wigley2, Ami A. Shah1, Andrea Corse3, Laura K. Hummers4 and Andrew Mammen5, 1Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, 3Neurology, Johns Hopkins University, Baltimore, MD, 4Johns Hopkins University School of Medicine, Baltimore, MD, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is associated with poor outcomes such as disability.  The spectrum of muscle histopathology of weak SSc patients is…
  • Abstract Number: 3069 • 2016 ACR/ARHP Annual Meeting

    Weight Loss in the Early Rheumatoid Arthritis Period Is Associated with Subsequent Increased Mortality in RA Patients and Matched Comparators: Evidence Against an RA-Specific Obesity Paradox

    Jeffrey A. Sparks1, Shun-Chiao Chang2, Uyen Sa D.T. Nguyen3,4, Medha Barbhaiya2, Sara K. Tedeschi2, Bing Lu2, Karen H. Costenbader2, Yuqing Zhang5, Hyon K. Choi6 and Elizabeth W. Karlson2, 1Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, 4Boston University School of Medicine, Boston, MA, 5Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA, 6Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

    Background/Purpose : Weight loss may explain the obesity paradox for mortality, since those who unintentionally lose weight to reach normal BMI may have higher mortality…
  • Abstract Number: 3070 • 2016 ACR/ARHP Annual Meeting

    Effect of Sarcopenia, Subcutaneous Adipose Tissue and Abdominal Visceral Fat on Mortality Risk of Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study

    Felipe M Santana1, Michel A Gonçalves2, Diogo S Domiciano3, Luana G Machado3, Jaqueline B Lopes3, Camille P Figueiredo3, Valéria Caparbo3, Liliam Takayama3 and Rosa M R Pereira4, 1Deparment of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Department of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil

    Background/Purpose:  Body composition changes resulting from ageing (decreased muscle mass and increased fat tissue) are frequently not accompanied by concomitant changes in body mass index…
  • Abstract Number: 3171 • 2016 ACR/ARHP Annual Meeting

    The Impact of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases

    April Jorge, Na Lu and Hyon K. Choi, Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Individuals with systemic autoimmune rheumatic diseases (SARDs)—such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc)—have been found to have an increased risk of…
  • Abstract Number: 3172 • 2016 ACR/ARHP Annual Meeting

    Temporal Trends in SLE Mortality According to Sex, Race, Ethnicity, and Geographic Region in the United States over the Past Five Decades

    Eric Yen1, Magda Shaheen2, Jennifer MP Woo1, Neil Mercer1, Lewei Duan1, Ning Li1, Arun Karlamangla1, Deborah K. McCurdy1 and Ram R. Singh1, 1UCLA, Los Angeles, CA, 2Charles R. Drew University of Medicine and Science, Los Angeles, CO

    Background/Purpose: Over the past half-century, diagnostic and therapeutic developments for SLE have led to dramatic improvements in the 5- and 10-year survival. Whether these achievements…
  • Abstract Number: 27 • 2016 ACR/ARHP Annual Meeting

    A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects

    Alfonse T. Masi1, Azeem A. Rehman2, Laura Jorgenson3 and Jean C. Aldag3, 1University of Illinois, College of Medicine at Peoria, Peoria, IL, 2Neurosurgery, University of West Virginia Medical School, Morgantown, WV, 3Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL

    Background/Purpose: Greater disease severity, older age, positive serum rheumatoid factor (RF), and long-standing glucocorticoid usage contribute to increased mortality of rheumatoid arthritis (RA) patients. This…
  • Abstract Number: 28 • 2016 ACR/ARHP Annual Meeting

    Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched Non-RA (CN) Subjects

    Alfonse T. Masi1, Azeem A. Rehman2, Laura Jorgenson3 and Jean C. Aldag3, 1University of Illinois, College of Medicine at Peoria, Peoria, IL, 2Neurosurgery, University of West Virginia Medical School, Morgantown, WV, 3Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL

    Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid…
  • Abstract Number: 41 • 2015 ACR/ARHP Annual Meeting

    Trends in Non-Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis: Is There Room for Improvement?

    Elena Myasoedova1, Cynthia S. Crowson2, Eric L. Matteson3, John M. Davis III4 and Sherine E. Gabriel5, 1Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Division of Rheumatology, Mayo Clinic, Rochester, MN, 5Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

    Background/Purpose: Rheumatoid arthritis (RA) is associated with increased all-cause and cause-specific mortality, including mortality from cardiovascular (CV) disease, respiratory causes, infections and malignancy. Evidence of…
  • Abstract Number: 42 • 2015 ACR/ARHP Annual Meeting

    Does the Risk of Mortality in Patients with RA Change over Time or Disease Duration?

    Kaleb Michaud1,2, Sofia Pedro2, Bryant R. England3 and Frederick Wolfe2, 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Observational studies have shown an increased risk of mortality in patients with RA, though none have done so with patients from all 50 US…
  • Abstract Number: 223 • 2015 ACR/ARHP Annual Meeting

    Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events

    Richard Conway1, Claire-Louise Murphy2, Anne Madigan2, Patricia Kavanagh2, Liz Geraghty2, Laura Helbert2, Kelly Stephens3, John J. Carey4, Eimear Dunne5, Dermot Kenny5 and Geraldine M. McCarthy6, 1Rheumatology, Mater Misericordiae University Hospital, Dublin 2, Ireland, 2Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 3Mater Misericordiae University Hospital, Clinical Research Center, Dublin, Ireland, 4Rheumatology, Galway University Hospitals, Galway, Ireland, 5Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, 6University College Dublin, Dublin, Ireland

    Background/Purpose: Patients with inflammatory arthritis, including gout, have an increased risk of cardiovascular events and mortality. Increased platelet reactivity is a risk marker for cardiovascular…
  • Abstract Number: 826 • 2015 ACR/ARHP Annual Meeting

    Systemic Sclerosis Inpatient Mortality Has Not Improved from 1995-2011. Results from a National Irish Audit of Scleroderma Co-Morbidities.

    Len Harty1, Deirdre Fitzgerald2, Michael Henry2, John Ryan3 and Sinead Harney3, 1Cork University Hospital, Cork, Ireland, 2Respiratory, Cork University Hospital, Cork, Ireland, 3Rheumatology, Cork University Hospital, Cork, Ireland

    Background/Purpose: Despite the advent of potent immunosuppressive and vasoactive therapies it is not clear that longevity of patients with systemic sclerosis (SSc) has improved. Therefore…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology